about
AR Signaling and the PI3K Pathway in Prostate CancerReal-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia.Dose considerations for anti-cancer drugs in metastatic prostate cancer.Outcomes of universal germline testing for men with prostate cancer in an Australian tertiary center
P50
description
researcher ORCID ID = 0000-0001-7213-900X
@en
name
Megan Crumbaker
@ast
Megan Crumbaker
@en
Megan Crumbaker
@es
Megan Crumbaker
@nl
type
label
Megan Crumbaker
@ast
Megan Crumbaker
@en
Megan Crumbaker
@es
Megan Crumbaker
@nl
prefLabel
Megan Crumbaker
@ast
Megan Crumbaker
@en
Megan Crumbaker
@es
Megan Crumbaker
@nl
P1153
56974505400
P31
P496
0000-0001-7213-900X